Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
It's a single molecule that activates three receptors simultaneously: GLP-1 (like semaglutide), GIP (like tirzepatide), and glucagon (new)
Journal of Clinical Medicine , 14(11), 3791
Food and Drug Administration, Understanding Investigational Drugs , April 2, 2019 GoodRx, Retatrutide for Weight Loss: Availability, Dosage, and More , June 25, 2026 Food and Drug Administration, Expanded Access, accessed June 29, 2026 Eli Lilly, Expanded Access | Compassionate Use | Clinical Trials , accessed June 29, 2026 WBUR | Here & Now, An extraordinary new obesity drug is still awaiting FDA approval
The Medicare GLP-1 Bridge seeks to test whether providing access to GLP-1 products at a uniform, CMS-negotiated net price will help improve beneficiary outcomes and reduce long-term Medicare spending, Kelly Strachan, CMS health insurance specialist and Innovation Center fellow, said, according to The Hill
